NCT04194034终止1 期
A Dose-escalation and Phase IIa Study of TG6002 Plus Flucytosine in Patients With Unresectable Colorectal Cancer With Liver Metastases
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 终止
- 发起方
- Transgene
- 入组人数
- 15
- 试验地点
- 3
- 主要终点
- Disease Control Rate (Phase II part)
研究概览
简要总结
This study will include two parts:
- Phase I part is a dose-escalation study to assess the safety of increasing doses of TG6002 in combination with oral flucytosine (5-FC) in consecutive cohorts of 3 to 6 patients with colorectal cancer and unresectable liver metastases according to a 3+3 design
- Phase IIa part is an extension of the phase I part at the recommended phase II dose to evaluate the efficacy of TG6002 in combination with oral flucytosine (5-FC) in patients with colorectal cancer and unresectable liver metastases.
In both parts, tumor response will be evaluated on local assessment using RECIST 1.1.
All patients will be followed until disease progression, death due to any cause or the date of data cut-off, whichever occurs first.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Unresectable metastatic CRC with at least one measurable liver metastasis
- •At least one liver metastasis amenable to biopsy
- •Patients previously exposed to fluoropyrimidine-based chemotherapy
- •(Phase I) Patients having failed, are intolerant to, or unsuitable for both oxaliplatin and irinotecan-based chemotherapy, or, in the UK only, patients on or entering a period of clinical observation without treatment
- •(Phase IIa) Patients having failed, are intolerant to, or unsuitable for both oxaliplatin and irinotecan-based chemotherapy.
- •Aged ≥18 years
- •Estimated life expectancy >3 months
- •ECOG performance status ≤1
排除标准
- •Predominant extrahepatic disease
- •Symptomatic brain metastases or meningeal tumors
- •Any contraindication to intrahepatic artery infusion procedure
- •Received other investigational therapy or had surgery within 4 weeks of treatment initiation which would interfere with study treatment
- •Received locoregional therapy for CRC within 4 weeks prior to treatment initiation
- •Severe uncontrolled coagulopathy OR anticoagulant medication
- •Antiviral therapy active on vaccinia virus, e.g., ribavirin, interferon/pegylated interferon
- •Immunosuppression due to immunosuppressive medication including steroids equivalent to prednisolone >10mg/day taken for more than 4 weeks within 3 months prior to TG6002 treatment initiation
- •Patients treated with 3 or more anti-hypertensive agents AND/OR patients with signs of advanced hypertensive disease, such as left ventricular hypertrophy, hypertensive encephalitis or history of hemorrhagic stroke.
研究组 & 干预措施
TG6002 and flucytosine (5-FC) combination
Experimental
干预措施: TG6002 (Biological)
TG6002 and flucytosine (5-FC) combination
Experimental
干预措施: Flucytosine (5-FC) (Drug)
结局指标
主要结局
Disease Control Rate (Phase II part)
时间窗: Week 10
Proportion of patients whose tumour assessment is either complete response (CR), partial response (PR), or stable disease (SD)
Dose-limiting toxicities (Phase I part)
时间窗: Day 28
Incidence of Adverse events using CTCAE v5.0
次要结局
未报告次要终点
研究者
研究点 (3)
Loading locations...
相似试验
尚未招募
1 期
A Study of MAX-40279combined With KN046 in Patients With Advanced / Metastatic Solid TumorsAdvanced / Metastatic Solid TumorsNCT05425602Maxinovel Pty., Ltd.108
终止
1 期
Study of TG6002 (VV TK-RR-FCU1) in Combination With 5-FC in Patients With Advanced Gastro-intestinal Tumors.Colorectal NeoplasmDigestive System NeoplasmNCT03724071Transgene51
进行中（未招募）
1 期
A Phase 1-2 Study of ST101 in Patients With Advanced Solid TumorsGlioblastomaMelanoma Stage IVBrain CancerMetastatic MelanomaMelanoma RecurrentBreast CancerProstate CancerMetastatic Breast CancerGBMProstate Cancer MetastaticNewly Diagnosed GlioblastomaRecurrent GlioblastomaMetastatic Prostate CancerGlioblastoma MultiformeNCT04478279Sapience Therapeutics125
招募中
1 期
Study of ZG005 in Combination With Etoposide and Cisplatin in Participants With Advanced Neuroendocrine Carcinoma.Neuroendocrine CarcinomaNCT06372626Suzhou Zelgen Biopharmaceuticals Co.,Ltd93
已完成
1 期
Phase 1 Every-3-Week Dosing of SCH 727965 in Patients With Advanced Cancer (Study P04630)Solid TumorsLymphoma, Non-HodgkinMultiple MyelomaNCT00871910Merck Sharp & Dohme LLC81